Series B Funded Startups in Japan
The largest disclosed Series B round in this Japan cohort is Sakana AI at $129M (2025-11-20).
The largest disclosed Series B round in this Japan cohort is Sakana AI at $129M (2025-11-20). That figure is a clear outlier versus the rest of the disclosed rounds, where amounts cluster mostly below $40M, including Forest at $40M (2025-10-12) and Metagen Therapeutics at $16M (2025-09-10), while other disclosed entries sit nearer the $3M–$11M range (for example, Nexta at $5M on 2025-11-27 and Opt Fit at $3M on 2025-11-16).
Geographically and temporally, entries cluster tightly: 18 of 19 rows fall between 2025-09-10 and the most recent date, 2025-11-27 (Nexta). Tokyo appears repeatedly as the operating city for multiple companies (e.g., Enerbank Japan, byFood.com, Ascend, Fivot, SecureNavi, Forest, Celaid Therapeutics, Ichirou, and Metagen Therapeutics), while Osaka and other cities show fewer repeats. Sector-wise, biotechnology/pharma shows up in at least three entries (Surv Biopharma $10M on 2025-11-11; Celaid Therapeutics $4M on 2025-10-11; Metagen Therapeutics $16M on 2025-09-10), and there is an opacity pattern: 3 of 19 rows list the round amount as “undisclosed” (Enerbank Japan 2025-11-25; EF Polymer 2025-10-02; AGRIST 2025-09-16).
Most recent rounds
19 shownRelated listings
Frequently asked
Which company has the largest disclosed Series B round here, and how does it compare to the rest of the disclosed amounts?
Sakana AI’s $129M round (2025-11-20) is the only disclosed entry above $50M and dwarfs the next-largest disclosed amount, Forest at $40M (2025-10-12). The majority of other disclosed rounds are comparatively smaller, such as Nexta at $5M (2025-11-27) and Opt Fit at $3M (2025-11-16).
Is there a concentrated time window among these 19 most recent rows?
Yes. Eighteen of 19 entries are dated between 2025-09-10 and 2025-11-27 (Nexta). The only earlier outlier is HekaBio at $4M on 2021-01-29.
Do any cities dominate, and is Tokyo more represented than other locations?
Tokyo is the most repeated location across multiple Series B entries, including Enerbank Japan (2025-11-25, undisclosed), byFood.com (2025-11-24, $4M), Ascend (2025-11-16, $7M), Fivot (2025-11-06, $6M), SecureNavi (2025-11-06, $8M), Forest (2025-10-12, $40M), Celaid Therapeutics (2025-10-11, $4M), Ichirou (2025-09-10, $8M), and Metagen Therapeutics (2025-09-10, $16M). Other cities (e.g., Osaka with Nexta on 2025-11-27) appear far less frequently in this view.
Are biotech/pharma rounds over-represented relative to other sectors in this list?
Biotechnology/pharmaceuticals appears in at least three entries: Surv Biopharma ($10M on 2025-11-11), Celaid Therapeutics ($4M on 2025-10-11), and Metagen Therapeutics ($16M on 2025-09-10). Other sectors show up in fewer entries within the 19-row window.
How common are undisclosed round sizes, and which entries are they?
3 of 19 rows list the Series B amount as “undisclosed”: Enerbank Japan (2025-11-25), EF Polymer (2025-10-02), and AGRIST (2025-09-16). These are interleaved across the same 2025 time cluster rather than being concentrated at the edges.
Which rounds are the closest ‘upper-mid’ contenders to the outlier $129M figure?
Beyond Sakana AI’s $129M, the next-highest disclosed round is Forest at $40M (2025-10-12), followed by Metagen Therapeutics at $16M (2025-09-10) and Fast Beauty at $11M (2025-11-15). Several other disclosed rounds sit in the single digits, such as Nexta at $5M (2025-11-27), Edeyans at $4M (2025-11-14), and Celaid Therapeutics at $4M (2025-10-11).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.